From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis-Reference-Cited by-同舟云学术

From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis

Published:2020-12-31 Issue:1 Volume:64 Page:385-403
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Jiang Bei-Er¹²,Jiang Xingwu¹³,Zhang Qiansen¹^ORCID,Liang Qiuwen¹,Qiu Zi-Liang¹,Sun Xiang-Bai¹,Yang Jun-Jie¹^ORCID,Chen Si¹,Yi Chunyang¹,Chai Xiaolei¹,Liu Mingyao¹^ORCID,Yu Li-Fang⁴^ORCID,Lu Weiqiang¹^ORCID,Zhang Han-Kun¹^ORCID

Affiliation:

1. Drug Discovery Unit, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, 500 Dongchuan Road, Shanghai 200241, P. R. China

2. Navy Medical Research Institute, Second Military Medical University, Shanghai 200433, P. R. China

3. Department of Materials Science, Fudan University, Shanghai 200433, P. R. China

4. Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, 3663 North Zhongshan Road, Shanghai 200062, P. R. China

Funder

East China Normal University

Ministry of Science and Technology of the People's Republic of China

Shanghai Municipal Education Commission

Science and Technology Commission of Shanghai Municipality

National Natural Science Foundation of China

Shenzhen Municipal

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link